Biseltadut medication

Biseltadut is a pharmaceutical product primarily known in the Spanish market for treating symptoms of benign prostatic hyperplasia. The product is manufactured in Spain, as indicated by the local address for Opella Healthcare Spain S.L. in Barcelona.

The brand is under the umbrella of Opella, which is the consumer healthcare division of the French pharmaceutical giant Sanofi. In early 2024, Sanofi began the process of separating Opella into a standalone business unit, often referred to as 'Grupo Sanofi' on packaging. As of late 2024 and heading into 2025, Sanofi entered exclusive negotiations with CD&R (Clayton, Dubilier & Rice) to sell a controlling stake in Opella, effectively shifting the ultimate ownership structure of these consumer brands while maintaining a presence in the global healthcare market.